Literature DB >> 22508959

Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.

Eugénie Lhommée1, Hélène Klinger, Stéphane Thobois, Emmanuelle Schmitt, Claire Ardouin, Amélie Bichon, Andrea Kistner, Valérie Fraix, Jing Xie, Magaly Aya Kombo, Stephan Chabardès, Eric Seigneuret, Alim-Louis Benabid, Patrick Mertens, Gustavo Polo, Sebastien Carnicella, Jean-Louis Quesada, Jean-Luc Bosson, Emmanuel Broussolle, Pierre Pollak, Paul Krack.   

Abstract

Addictions to dopaminergic drugs or to pleasant behaviours are frequent and potentially devastating neuropsychiatric disorders observed in Parkinson's disease. They encompass impulse control disorders, punding and dopamine dysregulation syndrome. A relationship with dopaminergic treatment is strongly suggested. Subthalamic stimulation improves motor complications and allows for drastic reductions in medication. This treatment might, therefore, be considered for patients with behavioural addictions, when attempts to reduce dopaminergic medication have failed. However, conflicting data have reported suppression, alleviation, worsening or new onset of behavioural addictions after subthalamic stimulation. Non-motor fluctuations are also a disabling feature of the disease. We prospectively investigated behaviour in a cohort of 63 patients with Parkinson's disease, before and 1 year after subthalamic stimulation using the Ardouin scale, with systematic evaluation of functioning in overall appetitive or apathetic modes, non-motor fluctuations, dopaminergic dysregulation syndrome, as well as behavioural addictions (including impulse control disorders and punding) and compulsive use of dopaminergic medication. Defined drug management included immediate postoperative discontinuation of dopamine agonists and reduction in levodopa. Motor and cognitive statuses were controlled (Unified Parkinson's Disease Rating Scale, Mattis Dementia Rating Scale, frontal score). After surgery, the OFF medication motor score improved (-45.2%), allowing for a 73% reduction in dopaminergic treatment, while overall cognitive evaluation was unchanged. Preoperative dopamine dysregulation syndrome had disappeared in 4/4, behavioural addictions in 17/17 and compulsive dopaminergic medication use in 9/9 patients. New onset of levodopa abuse occurred in one patient with surgical failure. Non-motor fluctuations were significantly reduced with improvements in off-dysphoria (P ≤ 0.001) and reduction in on-euphoria (P ≤ 0.001). There was an inversion in the number of patients functioning in an overall appetitive mode (29 before versus 2 after surgery, P ≤ 0.0001) to an overall apathetic mode (3 before versus 13 after surgery, P < 0.05). Two patients attempted suicide. Improvement in motor fluctuations is linked to the direct effect of stimulation on the sensory-motor subthalamic territory, while improvement in dyskinesias is mainly explained by an indirect effect related to the decrease in dopaminergic drugs. Our data suggest that non-motor fluctuations could similarly be directly alleviated through stimulation of the non-motor subthalamic territories, and hyperdopaminergic side effects might improve mainly due to the decrease in dopaminergic medication. We show an overall improvement in neuropsychiatric symptomatology and propose that disabling non-motor fluctuations, dopaminergic treatment abuse and drug-induced behavioural addictions in Parkinson's disease may be considered as new indications for subthalamic stimulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508959     DOI: 10.1093/brain/aws078

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  77 in total

1.  Informed Consent in Implantable BCI Research: Identifying Risks and Exploring Meaning.

Authors:  Eran Klein
Journal:  Sci Eng Ethics       Date:  2015-10-23       Impact factor: 3.525

Review 2.  Neuromodulation interventions for addictive disorders: challenges, promise, and roadmap for future research.

Authors:  Primavera A Spagnolo; David Goldman
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

Review 3.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 4.  Deep brain stimulation for the treatment of addiction: basic and clinical studies and potential mechanisms of action.

Authors:  R Christopher Pierce; Fair M Vassoler
Journal:  Psychopharmacology (Berl)       Date:  2013-08-02       Impact factor: 4.530

5.  Modification of spectral features by nonhuman primates.

Authors:  Daniel J Weiss; Cara F Hotchkin; Susan E Parks
Journal:  Behav Brain Sci       Date:  2014-12       Impact factor: 12.579

Review 6.  New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.

Authors:  Giacomo Grassi; Giovanni Albani; Federica Terenzi; Lorenzo Razzolini; Silvia Ramat
Journal:  Neurol Sci       Date:  2021-04-14       Impact factor: 3.307

7.  Targeting the subthalamic nucleus in a preclinical model of alcohol use disorder.

Authors:  Yann Pelloux; Christelle Baunez
Journal:  Psychopharmacology (Berl)       Date:  2017-04-11       Impact factor: 4.530

8.  The Influence of Bilateral Subthalamic Nucleus Deep Brain Stimulation on Impulsivity and Prepulse Inhibition in Parkinson's Disease Patients.

Authors:  Lucy Gee; Heather Smith; Priscilla De La Cruz; Joannalee Campbell; Chris Fama; Jessica Haller; Adolfo Ramirez-Zamora; Jennifer Durphy; Era Hanspal; Eric Molho; Anne Barba; Damian Shin; Julie G Pilitsis
Journal:  Stereotact Funct Neurosurg       Date:  2015-06-10       Impact factor: 1.875

Review 9.  Effect of subthalamic deep brain stimulation on non-motor fluctuations in Parkinson's disease.

Authors:  Jean-Philippe Azulay; Tatiana Witjas; Alexandre Eusebio
Journal:  J Neural Transm (Vienna)       Date:  2012-12-23       Impact factor: 3.575

10.  STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.

Authors:  Nolan R Williams; Kelly D Foote; Michael S Okun
Journal:  Mov Disord Clin Pract       Date:  2014-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.